COMMUNIQUÉS West-GlobeNewswire

-
Virbac : Déclaration d'actions et de droits de vote 11/2024
06/12/2024 -
CHEO Research Institute and Shriners Hospitals for Children Canada Collaborate to Launch First-of-its-kind Joint Pediatric Metabolic and Genetic Bone Disorders Fellowship
06/12/2024 -
L'Institut de recherche du CHEO et les Hôpitaux Shriners pour enfants Canada collaborent en lançant le premier programme de Monitorat clinique conjoint sur les troubles métaboliques et génétiques de l’os chez l'enfant
06/12/2024 -
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
06/12/2024 -
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06/12/2024 -
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
06/12/2024 -
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06/12/2024 -
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
06/12/2024 -
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
06/12/2024 -
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024 -
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024 -
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
06/12/2024 -
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06/12/2024 -
FluidForm Bio™ Announces Participation in the New England Venture Summit
06/12/2024 -
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
06/12/2024 -
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
06/12/2024 -
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
06/12/2024 -
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
06/12/2024 -
Profound Medical Announces Proposed Public Offering of Common Shares
05/12/2024
Pages